Use of masitinib in combination with gemcitabine to treat a subgroup of patients suffering from pancreatic cancer

摘要

Masitinib or a pharmaceutically acceptable salt thereof in combination with gemcitabine for use in the treatment of pancreatic cancer in a human patient, wherein said patient is initially selected for treatment based on the disease-related pain intensity predictor, defined as at least one reported occurrence of a one-dimensional pain intensity assessment tool score greater than 20%.